期刊文献+

阿尔茨海默病的免疫治疗:现状及思考 被引量:4

下载PDF
导出
摘要 阿尔茨海默病(Alzheimerdisease,AD)占全部痴呆的60%-70%。美国目前AD患者约占痴呆总人数的60%。AD的发病机制主要与β淀粉样前体蛋白(APP)抑制乙酰胆碱通路、淀粉样沉积、tau蛋白磷酸化、氧化压力、金属离子失调和炎症以及胆固醇和谷氨酸盐的参与有关。β淀粉样蛋白(Aβ)是老年斑的主要成分,在AD发病中起关键作用。
出处 《实用医学杂志》 CAS 北大核心 2014年第11期1842-1844,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献19

  • 1高云天,赵强,卢小青,王广新,孔润莲,侯淑莲.^(18)F-FDG PET对Alzheimer病的研究[J].中国煤炭工业医学杂志,2011,14(6):845-846. 被引量:3
  • 2朱建忠,莫克强,李淳.血管性痴呆与阿尔茨海默病的精神行为症状分析[J].河北医学,2010,16(4):440-442. 被引量:6
  • 3孙争宇,索爱琴,张杰文,李玮,吕娟.Aβ_(1~42)致老年性痴呆大鼠海马神经元细胞外信号调节激酶1,2的表达[J].中华实用诊断与治疗杂志,2009,23(2):151-153. 被引量:4
  • 4杨春水,刘人恺,杨志刚,李建英,林勤郁,李雯飞,金明月.老年痴呆患者社会支持度对其生存质量的影响观察[J].河北医学,2013,19(2):207-209. 被引量:7
  • 5Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non- steroidalanti. Inflammaory drugs for the treatment of Alzheimer' s disease [J]. Cochrane Data-base Syst Rev, 2012, (2) : CD006378.
  • 6Vellas B, Black R, Thai LJ, et al. AN1792 (QS0-21)-251 Study Team. Long-term Follow-up of patients immunized with AN1792 : reduced functional decline in antibody responders [J]. Curt Alzheimer Res, 2009,6(2) : 144-151.
  • 7Orgogozo JM, Gilman S, Dartigues JF, et al. Subaeute meningoencephalitis in a subset of patients with AD after A(beta) 42 immunization [J]. Neurology, 2008, 61 (1) :46-54.
  • 8Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunization in Alzheimer' s disease: follow-up of a randomised,placebo- controlled phase I trial [J]. Lancet, 2009,372(9634) : 216-223.
  • 9Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease [J]. Neurology, 2009,73(24) :2061-2070.
  • 10Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer' s disease treated with bapineuzumab : a retrospective analysis [J]. Lancet Neurol, 2012,11(3) :241-249.

二级参考文献30

  • 1吴义根,李可.SPM软件包数据处理原理简介——第一部分:基本数学原理[J].中国医学影像技术,2004,20(11):1768-1772. 被引量:26
  • 2张西菊,马有娣,魏红艳.行为干预方法对老年痴呆患者生存质量的影响[J].中国康复医学杂志,2006,21(6):551-552. 被引量:16
  • 3Bowler JV,Gorelick PB.Advances in vascular cognitive impairment 2006[J].Stroke,2007,38(2):241-244.
  • 4Gold G,Bouras C,Canuto A,et al.Clinicopathological validation study of four sets of clinical critical for vascular dementia[J].Am Psychiatry,2002,159(1):82.
  • 5Black W,Almelda OP.A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care[J].Int Psychogeriatr,2004,16(3):295.
  • 6Ringheim GE,Szczepanik AM.Brain inflammation,cholesterol and glutamate as interconnected participants in the pathology of Alzheimer's disease[J].Curr Pharm Des,2006,12(6):719-738.
  • 7Scalco MZ,van Reekum R.Prevention of Alzheimer disease.Encouraging evidence[J].Can Faro Physician,2006,52:200-207.
  • 8Jellinger KA.Morphologic diagnosis of"vascular dementia"-a critical update[J].Neurol Sci,2008,270(1-2):1-12.
  • 9Ingles JL,Bouhon DC,Fisk JD,et al.Preclinical vascular cognitive impairment and Alzheimer disease:neuropsychological test performance 5 years before diagnosis[J].Stroke,2007,38(4):1148-1153.
  • 10Reed BR,Mungas DM,Kramer JH,et al.Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease[J].Brain,2007,130,3:731-739.

共引文献19

同被引文献56

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部